Cargando…

Platelet-derived circRNAs signature in patients with gastroenteropancreatic neuroendocrine tumors

BACKGROUND: Neuroendocrine tumors (NETs) early diagnosis is a clinical challenge that require a deep understanding of molecular and genetic features of this heterogeneous group of neoplasms. However, few biomarkers exist to aid diagnosis and to predict prognosis and treatment response. In the oncolo...

Descripción completa

Detalles Bibliográficos
Autores principales: Campolo, Federica, Sesti, Franz, Feola, Tiziana, Puliani, Giulia, Faggiano, Antongiulio, Tarsitano, Maria Grazia, Tenuta, Marta, Hasenmajer, Valeria, Ferretti, Elisabetta, Verrico, Monica, Gianfrilli, Daniele, Venneri, Mary Anna, Isidori, Andrea M., Giannetta, Elisa
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10428534/
https://www.ncbi.nlm.nih.gov/pubmed/37587471
http://dx.doi.org/10.1186/s12967-023-04417-8
_version_ 1785090493198106624
author Campolo, Federica
Sesti, Franz
Feola, Tiziana
Puliani, Giulia
Faggiano, Antongiulio
Tarsitano, Maria Grazia
Tenuta, Marta
Hasenmajer, Valeria
Ferretti, Elisabetta
Verrico, Monica
Gianfrilli, Daniele
Venneri, Mary Anna
Isidori, Andrea M.
Giannetta, Elisa
author_facet Campolo, Federica
Sesti, Franz
Feola, Tiziana
Puliani, Giulia
Faggiano, Antongiulio
Tarsitano, Maria Grazia
Tenuta, Marta
Hasenmajer, Valeria
Ferretti, Elisabetta
Verrico, Monica
Gianfrilli, Daniele
Venneri, Mary Anna
Isidori, Andrea M.
Giannetta, Elisa
author_sort Campolo, Federica
collection PubMed
description BACKGROUND: Neuroendocrine tumors (NETs) early diagnosis is a clinical challenge that require a deep understanding of molecular and genetic features of this heterogeneous group of neoplasms. However, few biomarkers exist to aid diagnosis and to predict prognosis and treatment response. In the oncological field, tumor-educated platelets (TEPs) have been implicated as central players in the systemic and local responses to tumor growth, thereby altering tumor specific RNA profile. Although TEPs have been found to be enriched in RNAs, few studies have investigated the potential of a type of RNA, circular RNAs (circRNA), as platelet-derived biomarkers for cancer. In this proof-of-concept study, we aim to demonstrate whether the circRNAs signature of tumor educated platelets can be used as a liquid biopsy biomarker for the detection of gastroenteropancreatic (GEP)-NETs and the prediction of the early response to treatment. METHODS: We performed a 24-months, prospective proof-of-concept study in men and women with histologically proven well-differentiated G1-G2 GEP-NET, aged 18–80 years, naïve to treatment. We performed a RNAseq analysis of circRNAs obtained from TEPs samples of 10 GEP-NETs patients at baseline and after 3 months from therapy (somatostatin analogs or surgery) and from 5 patients affected by non-malignant endocrinological diseases enrolled as a control group. RESULTS: Statistical analysis based on p < 0.05 resulted in the identification of 252 circRNAs differentially expressed between GEP-NET and controls of which 109 were up-regulated and 143 were down-regulated in NET patients. Further analysis based on an FDR value ≤ 0.05 resulted in the selection of 5 circRNAs all highly significant downregulated. The same analysis on GEP-NETs at baseline and after therapy in 5 patients revealed an average of 4983 remarkably differentially expressed circRNAs between follow-up and baseline samples of which 2648 up-regulated and 2334 down-regulated, respectively. Applying p ≤ 0.05 and FDR ≤ 0.05 filters, only 3/5 comparisons gave statistically significant results. CONCLUSIONS: Our findings identified for the first time a circRNAs signature from TEPs as potential diagnostic and predictive biomarkers for GEP-NETs. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12967-023-04417-8.
format Online
Article
Text
id pubmed-10428534
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-104285342023-08-17 Platelet-derived circRNAs signature in patients with gastroenteropancreatic neuroendocrine tumors Campolo, Federica Sesti, Franz Feola, Tiziana Puliani, Giulia Faggiano, Antongiulio Tarsitano, Maria Grazia Tenuta, Marta Hasenmajer, Valeria Ferretti, Elisabetta Verrico, Monica Gianfrilli, Daniele Venneri, Mary Anna Isidori, Andrea M. Giannetta, Elisa J Transl Med Research BACKGROUND: Neuroendocrine tumors (NETs) early diagnosis is a clinical challenge that require a deep understanding of molecular and genetic features of this heterogeneous group of neoplasms. However, few biomarkers exist to aid diagnosis and to predict prognosis and treatment response. In the oncological field, tumor-educated platelets (TEPs) have been implicated as central players in the systemic and local responses to tumor growth, thereby altering tumor specific RNA profile. Although TEPs have been found to be enriched in RNAs, few studies have investigated the potential of a type of RNA, circular RNAs (circRNA), as platelet-derived biomarkers for cancer. In this proof-of-concept study, we aim to demonstrate whether the circRNAs signature of tumor educated platelets can be used as a liquid biopsy biomarker for the detection of gastroenteropancreatic (GEP)-NETs and the prediction of the early response to treatment. METHODS: We performed a 24-months, prospective proof-of-concept study in men and women with histologically proven well-differentiated G1-G2 GEP-NET, aged 18–80 years, naïve to treatment. We performed a RNAseq analysis of circRNAs obtained from TEPs samples of 10 GEP-NETs patients at baseline and after 3 months from therapy (somatostatin analogs or surgery) and from 5 patients affected by non-malignant endocrinological diseases enrolled as a control group. RESULTS: Statistical analysis based on p < 0.05 resulted in the identification of 252 circRNAs differentially expressed between GEP-NET and controls of which 109 were up-regulated and 143 were down-regulated in NET patients. Further analysis based on an FDR value ≤ 0.05 resulted in the selection of 5 circRNAs all highly significant downregulated. The same analysis on GEP-NETs at baseline and after therapy in 5 patients revealed an average of 4983 remarkably differentially expressed circRNAs between follow-up and baseline samples of which 2648 up-regulated and 2334 down-regulated, respectively. Applying p ≤ 0.05 and FDR ≤ 0.05 filters, only 3/5 comparisons gave statistically significant results. CONCLUSIONS: Our findings identified for the first time a circRNAs signature from TEPs as potential diagnostic and predictive biomarkers for GEP-NETs. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12967-023-04417-8. BioMed Central 2023-08-16 /pmc/articles/PMC10428534/ /pubmed/37587471 http://dx.doi.org/10.1186/s12967-023-04417-8 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Campolo, Federica
Sesti, Franz
Feola, Tiziana
Puliani, Giulia
Faggiano, Antongiulio
Tarsitano, Maria Grazia
Tenuta, Marta
Hasenmajer, Valeria
Ferretti, Elisabetta
Verrico, Monica
Gianfrilli, Daniele
Venneri, Mary Anna
Isidori, Andrea M.
Giannetta, Elisa
Platelet-derived circRNAs signature in patients with gastroenteropancreatic neuroendocrine tumors
title Platelet-derived circRNAs signature in patients with gastroenteropancreatic neuroendocrine tumors
title_full Platelet-derived circRNAs signature in patients with gastroenteropancreatic neuroendocrine tumors
title_fullStr Platelet-derived circRNAs signature in patients with gastroenteropancreatic neuroendocrine tumors
title_full_unstemmed Platelet-derived circRNAs signature in patients with gastroenteropancreatic neuroendocrine tumors
title_short Platelet-derived circRNAs signature in patients with gastroenteropancreatic neuroendocrine tumors
title_sort platelet-derived circrnas signature in patients with gastroenteropancreatic neuroendocrine tumors
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10428534/
https://www.ncbi.nlm.nih.gov/pubmed/37587471
http://dx.doi.org/10.1186/s12967-023-04417-8
work_keys_str_mv AT campolofederica plateletderivedcircrnassignatureinpatientswithgastroenteropancreaticneuroendocrinetumors
AT sestifranz plateletderivedcircrnassignatureinpatientswithgastroenteropancreaticneuroendocrinetumors
AT feolatiziana plateletderivedcircrnassignatureinpatientswithgastroenteropancreaticneuroendocrinetumors
AT pulianigiulia plateletderivedcircrnassignatureinpatientswithgastroenteropancreaticneuroendocrinetumors
AT faggianoantongiulio plateletderivedcircrnassignatureinpatientswithgastroenteropancreaticneuroendocrinetumors
AT tarsitanomariagrazia plateletderivedcircrnassignatureinpatientswithgastroenteropancreaticneuroendocrinetumors
AT tenutamarta plateletderivedcircrnassignatureinpatientswithgastroenteropancreaticneuroendocrinetumors
AT hasenmajervaleria plateletderivedcircrnassignatureinpatientswithgastroenteropancreaticneuroendocrinetumors
AT ferrettielisabetta plateletderivedcircrnassignatureinpatientswithgastroenteropancreaticneuroendocrinetumors
AT verricomonica plateletderivedcircrnassignatureinpatientswithgastroenteropancreaticneuroendocrinetumors
AT gianfrillidaniele plateletderivedcircrnassignatureinpatientswithgastroenteropancreaticneuroendocrinetumors
AT vennerimaryanna plateletderivedcircrnassignatureinpatientswithgastroenteropancreaticneuroendocrinetumors
AT isidoriandream plateletderivedcircrnassignatureinpatientswithgastroenteropancreaticneuroendocrinetumors
AT giannettaelisa plateletderivedcircrnassignatureinpatientswithgastroenteropancreaticneuroendocrinetumors